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Abstract 
Equine influenza virus (EIV) causes a highly contagious disease in horses and other equids. Recently, we isolated an 
H3N8 EIV (A/equine/Kyonggi/SA1/2011) from a domestic horse in South Korea that exhibited symptoms of respira‑
tory disease, and found that the EIV strain contained a naturally mutated NS gene segment encoding a truncated NS1 
protein. In order to determine whether there was an association between the NS gene truncation and viral virulence, 
a reverse genetics system was applied to generate various NS gene recombinant viruses using the backbone of the 
H1N1 A/Puerto Rico/8/1934 (PR/8) virus. In a mouse model, the recombinant PR/8 virus containing the mutated NS 
gene of the Korean H3N8 EIV strain showed a dramatically reduced virulence: it induced no weight loss, no clinical 
signs and no histopathological lesions. However, the mice infected with the recombinant viruses with NS genes of 
PR/8 and H3N8 A/equine/2/Miami/1963 showed severe clinical signs including significant weight loss and 100% mor‑
tality. In addition, the levels of the pro‑inflammatory cytokines; IL‑6, CCL5, and IFN‑γ, in the lungs of mice infected with 
the recombinant viruses expressing a full‑length NS1 were significantly higher than those of mice infected with the 
virus with the NS gene from the Korean H3N8 EIV strain. In this study, our results suggest that the C‑terminal moiety 
of NS1 contains a number of virulence determinants and might be a suitable target for the development of a vaccine 
candidate against equine influenza.
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Equine influenza virus (EIV), which is a member of the 
genus Orthomyxovirus, family Orthomyxoviridae, con-
tains a single-stranded, negative-sense RNA in the fol-
lowing eight gene segments: PB2, PB1, PA, HA, NP, NA, 
M, and NS. This virus is the causative agent of serious 
respiratory diseases in horses [1]. There are two distinct 
influenza A virus subtypes in horses; H7N7 and H3N8. 
Although H7N7 viruses are no longer circulating in 
horse populations, H3N8 EIV is continuously isolated in 
Europe, North America, North Africa, and Asia, includ-
ing South Korea [1, 2]. It was demonstrated that H3N8 
EIV was responsible for the emergence of H3N8 canine 
influenza A virus (CIV) in North America in 2004 [3]. 
Genetic analysis revealed that H3N8 CIV originated in 
a racing greyhound that was previously infected with an 
H3N8 EIV, and this emergent H3N8 CIV, the representa-
tive subtype of CIV in North America, is still circulating 
in pet dogs [3, 4]. Furthermore, two strains of H3N8 EIV 
were detected in pigs in China [5]. Thus, H3N8 EIV seems 
to have the potential to cross the host barrier among ani-
mal species. Recently, we isolated from a domestic horse 
in South Korea an H3N8 EIV strain (A/equine/Kyonggi/
SA1/2011; KYG11) belonging to the Florida sublineage 
clade 1 [2]. Interestingly, the KYG11 strain possessed an 
NS gene segment that harbored a deletion of nucleotides 
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326 to 348 of NS1 open reading frame, resulting in a 
frameshift and a premature stop codon. The encoded NS1 
protein was 117 amino acids long [2].
The NS gene of influenza viruses encodes two different 
nonstructural proteins, NS1 and nuclear export protein. 
The NS1 protein is known to play a role in the enhance-
ment of influenza virus replication by antagonizing inter-
feron (IFN) production in host cells [6, 7]. In contrast, the 
replication ability of influenza viruses with a truncated 
NS1 gene is markedly decreased by inhibited IFN-medi-
ated anti-viral responses in host cells [6–8]. Previous 
studies have shown that a deletion in the NS1 gene may 
be associated with the virulence of several subtypes of 
influenza A viruses such as H3N2 and H5N1 in several 
animal species [9–11].
Therefore, it was hypothesized that the virulence of 
the Korean H3N8 EIV strain, KYG11, is influenced by 
the mutated NS gene. In this study, we aimed at eluci-
dating the effect of the 23 nt deletion within the NS gene 
in  vivo and in  vitro and used a reverse genetics system 
to generate recombinant influenza viruses containing the 
truncated NS gene of KYG11 or different NS genes from 
other influenza viruses. The NS gene of KYG11 affected 
the virulence and immune-pathogenic properties of PR/8 
virus in  vivo and the results provide important insights 
into this Korean EIV strain, indicating that a specific 
region of the NS1 gene confers pathogenicity in mice.
Materials and methods
Cells
Madin-Darby canine kidney (MDCK, ATCC CRL-2936) 
cells, human pulmonary epithelial (A549) cells, and 
human embryonic kidney (293T) cells were obtained 
from the American Type Culture Collection (ATCC). The 
MDCK and A549 cells were grown in Dulbecco’s modi-
fied Eagle’s medium (DMEM, Gibco, Carlsbad, CA, USA) 
containing 10% fetal bovine serum (FBS) and antibiot-
ics. The 293T cells were cultured in Opti-MEM (Gibco) 
supplemented with 5% FBS and antibiotics. All cells were 
maintained at 37 °C in 5% CO2.
Viruses
The novel H3N8 EIV strain; A/equine/Kyonggi/
SA1/2011(KYG11) and H3N8 A/equine/2/Miami/1963 
(MA63) were obtained from the ATCC and propagated 
in the allantoic cavity of 10-day-old embryonated chicken 
eggs. The eight-plasmid-based reverse genetics system 
was kindly provided by Dr Richard J. Webby (St. Jude 
Children’s Research Hospital, TN, USA).
Generation of recombinant viruses
Viral RNA was extracted from the allantoic fluid using a 
QIAamp Viral RNA Mini Kit (Qiagen Inc., Valencia, CA, 
USA). The RNA was reverse transcribed and NS genes 
were amplified by PCR using a OneStep reverse tran-
scription PCR kit (Qiagen Inc.) with universal primers 
and then cloned into a pHW2000 plasmid. We used the 
plasmid-based reverse genetics system to generate the 
reverse genetics viruses [12, 13].
Briefly, eight pHW2000 plasmids, each containing 
an individual gene of the eight influenza A virus genes, 
were transfected into co-cultured MDCK and 293T cells. 
Recombinant PR/8 (rPR/8) and the following NS-gene 
reassortant viruses were rescued from the plasmids: 
PR/8 × NS KYG11 (rPR/8 × KYGNS) and PR/8 × NS A/
equine/2/Miami/1963 (rPR/8 ×  MINS). The supernatant 
collected from transfected cells was used to inoculate 
10-day-old embryonated chicken eggs for virus propaga-
tion. After the generation of the recombinant viruses, the 
full genome sequences of the viruses were verified with 
an RT-PCR and sequencing analysis. Virus stocks were 
stored at −80 °C until use.
Western blotting and plaque assay
For immunoblotting, MDCK cells infected with the 
viruses were lysed in RIPA lysis buffer (1% Triton X-100, 
1% deoxycholate, and 0.1% SDS). The proteins were then 
separated on 10% SDS polyacrylamide gels, then trans-
ferred onto a nitrocellulose membrane. The membrane 
was blocked in 5% skimmed milk buffer, then stained 
using primary monoclonal mouse antibodies against 
influenza A NS1 protein (1:2000; sc-130568; Santa Cruz, 
Dallas, TX, USA) and monoclonal mouse antibodies 
against influenza A virus NP protein (1:2000; sc-80481; 
Santa Cruz) at 4 °C overnight. For protein detection, the 
membrane was incubated with anti-mouse IgG HRP-
conjugated secondary antibody and visualized using 
the ATTO Ez-Capture II system (ATTO, Japan). For the 
plaque assay, MDCK cells plated in 6-well tissue cul-
ture plates were inoculated with tenfold serially diluted 
viruses. After adsorption for 1  h, the cells were washed 
and overlaid with 1% low-melting agarose in DMEM con-
taining 2% FBS. After incubation at 37  °C for 72  h, the 
agarose was gently removed and plaques were visualized 
with crystal violet staining.
Virus replication kinetics
To evaluate the kinetics of virus replication in  vitro, 
allantoic fluid containing rPR/8, rPR/8  ×  KYGNS, or 
rPR/8  ×  MINS viruses was harvested, and MDCK and 
A549 cells were infected with the viruses at a multiplicity 
of infection (MOI) of 0.01 plaque forming unit per cell. 
The virus inocula were removed after 1 h. The cells were 
then washed and infection medium containing 1 μg/mL 
TPCK-treated trypsin was added. Supernatants were col-
lected 12, 24, 36, 48, and 72 h post-inoculation and stored 
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at −80 °C for titration by TCID50 assay. The TCID50 was 
calculated by the method of Reed and Muench [14]. The 
limit of detection was 10 TCID50/mL. In addition, the 
kinetics of the harvested viruses was determined by inoc-
ulating 10-day-old embryonated chicken eggs with serial 
dilutions of viruses. The limit of detection of the assay 
was 10 EID50/mL.
Mouse experiments
All animal experiments were performed in biosafety-
level-2 facilities at the Korean Research Institute of Bio-
science and Biotechnology (Daejeon, South Korea). We 
followed the General Animal Care Guideline as required 
by the Institutional Animal Care and Use Committee of 
the institute (Approval Number: # KRIBB-ACE-14096).
To determine the 50% mouse lethal dose (MLD50) of 
each virus, 6-week-old C57BL/6 mice (Korea Animal 
Technology, Pyeongtaek, South Korea) were inoculated 
intranasally with tenfold serial dilutions containing 102 to 
108 EID50 of each virus in a 30  μL volume. The MLD50 
was calculated using the method of Reed and Muench. 
To compare the virulence of the rPR/8, rPR/8 × KYGNS, 
and rPR/8 × MINS viruses, ten mice were used to moni-
tor the survival rates and body weights, and another 
twelve mice were used for lung titration of each recombi-
nant virus strain. The anesthetized mice were inoculated 
intranasally with 300 EID50 (in a 30 μL volume) of each 
virus into a single nostril. For the mock control group, 
ten and twelve mice inoculated with phosphate-buffered 
saline (PBS) were used for body weight measurement and 
lung titration, respectively.
For virus titration in the lungs, three mice in the 
infection group were sacrificed at 3, 5, 7, and 9  days 
post-infection (dpi), and lung tissues were collected 
and homogenized in 1  mL of PBS with antibiotics. 
The supernatant collected from the homogenized tis-
sue was titrated in eggs. All mice were monitored daily 
for 14 days for weight changes and mortality, and mice 
that lost more than 25% of their body weight were 
euthanized.
Histopathological examination
Lung tissue samples were harvested from the mice on 
7 dpi. The samples were collected in 10% buffered forma-
lin to fix the tissues and were then embedded in paraf-
fin wax, sectioned (4–5  μm thick sections), and placed 
on glass slides. For the histological examination of the 
tissues, they were stained with hematoxylin and eosin 
(H&E) and examined by a pathologist.
Cytokine assay
The cytokine level in bronchoalveolar lavage (BAL) fluid 
was determined using a Bio-Plex Pro™ cytokine assay 
kit (Bio-Rad, Hercules, CA, USA). The pro-inflamma-
tory cytokines: interleukin (IL)-6, interferon-gamma 
(IFN-γ, and CCL5 (RANTES; regulated upon activation 
normal T cell expressed and presumably secreted) were 
measured according to the manufacturer’s instructions. 
Briefly, 50  μL BAL fluid samples were incubated with 
antibody-coupled beads. These immune complexes were 
washed and incubated first with a biotinylated detection 
antibody and then with streptavidin–phycoerythrin prior 
to assessing the cytokine concentration. The pro-inflam-
matory cytokine levels were determined using a Bio-Plex 
200 System multiplex array reader (Bio-Rad) using soft-
ware provided by the manufacturer (Bio-Plex Manager 
Software 4.1.1).
Statistical analysis
The data for body weight changes, viral titers, and lev-
els of the pro-inflammatory cytokines in the lungs of the 
mice were analyzed by the two-way ANOVA with Bon-
ferroni post-tests. Statistical analyses were performed 
using GraphPad Prism version 5 (GraphPad Software, La 




To determine the functionality of the deleted nucleo-
tides in the truncated NS gene, we successfully gener-
ated reverse genetics viruses; rPR/8, rPR/8 × MINS; and 
rPR/8  ×  KYGNS. As a first attempt to characterize the 
three recombinant viruses, their sequences were checked, 
and we confirmed that cells infected with the recombi-
nant virus rPR/8  ×  KYGNS virus expressed a  ~15  kDa 
NS1; however full-length NS1protein of approximately 
26  kDa was revealed for the rPR/8 and rPR/8  ×  MINS 
viruses by western blotting (Figure 1A).
The growth properties of the three viruses were deter-
mined in embryonated chicken eggs. All of the reverse 
genetics viruses grew to high titers in eggs (Table 1), with 
endpoint titers after a single egg passage reaching 107.9 
EID50/mL for rPR/8, 108.1 EID50/mL for rPR/8 ×  MINS, 
and 108.3 EID50/mL for rPR/8 × KYGNS.
Next, how the truncated NS gene affected the 
growth kinetics of the viruses was determined in  vitro. 
We infected MDCK and A549 cells with the rPR/8, 
rPR/8 ×  KYGNS and rPR/8 ×  MINS viruses at an MOI 
of 0.01 and observed their growth kinetics for 72 h. We 
found that all recombinant viruses grow to a similar 
titer in both cell lines at each time point, indicating that 
the truncated NS gene did not substantially affect the 
replicative capacity of these viruses in cell culture (Fig-
ures 1B and C). In addition, all three viruses displayed the 
same plaque phenotype at 37 °C (Figure 1D).
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Virulence of recombinant viruses in mice
To evaluate how the truncated NS gene affected viru-
lence in vivo, we inoculated mice with the recombinant 
viruses. The rPR/8 and rPR/8  ×  MINS viruses showed 
comparable virulence, with MLD50 of 104.25 and 103.92 
EID50, respectively, whereas the rPR/8 × KYGNS recom-
binant showed significant attenuation, with an MLD50 
value of 107.75 (Table 1). To further investigate the viru-
lence of these viruses in mice, we inoculated mice with 
300 EID50 (in a 30 μL volume) of each recombinant virus 
Figure 1 Western blot analysis, growth kinetics, and plaque phenotyping of the recombinant viruses. Immunoblot of the NS1 protein 
in extracts from MDCK cells infected with PR/8, PR/8 × KYGNS, and PR/8 × MINS viruses at an MOI of 1 for 12 h (A). The protein was detected using 
a mouse anti‑NS1 primary antibody, and the molecular weight in kDa is shown on the left of the membrane. MDCK (B) and A549 (C) cells were 
infected with the PR/8, PR/8 × KYGNS, or PR/8 × MINS virus at an MOI of 0.01, and the virus was titrated in the supernatant that was collected at 
the indicated time points. The detection limit was 1 log10 TCID50/mL (dotted line). Data are shown as the mean ± standard deviation from three 
independent experiments. Plaque assay performed with PR/8, PR/8 × KYGNS, and PR/8 × MINS viruses (D). The tissue culture plates infected with the 
viruses were fixed and stained with crystal violet dye.
Table 1 Characteristics of the recombinant viruses
Virus titer in embryonated eggs, MLD50 (expressed in EID50 units).
MLD: mouse lethal dose, EID: egg infectious dose.
a The EID50 was calculated by the Reed and Muench method.
b N: 10 for each virus infection group.




PR/8 × MINS 108.1 104.3
PR/8 × KYGNS 108.3 107.8
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and evaluated clinical signs, mortality, weight loss, and 
viral load in the lungs. Virus replication kinetics in the 
lung was determined by measuring virus titers at 3, 5, 7, 
and 9 dpi.
The virus titers in mice infected with rPR/8 × KYGNS 
were at least one hundred to one thousand fold lower 
than the virus loads in the lungs of mice inoculated with 
the two other viruses (Figure  2A). The body weights of 
mice inoculated with rPR/8 × KYGNS gradually increased 
from 1 to 14  dpi. In contrast, there was rapid and dra-
matic weight loss of over 25% in the mice infected with 
rPR/8 or rPR/8  ×  MINS (Figure  2B). The mice infected 
with rPR/8  ×  KYGNS exhibited no clinical signs and 
showed 100% survival. In contrast, all mice infected with 
rPR/8 or rPR/8 × MINS exhibited progressive signs such 
as inactivity, ruffled fur, lack of appetite, hunched backs, 
and labored breathing (Figure 2C).
Pulmonary histopathology in mice inoculated 
with recombinant viruses
To examine viral pathology, we performed H&E staining 
on lung tissues collected on days 7 post-infection from 
three mice. Mice infected with PBS or rPR/8 ×  KYGNS 
showed normal lung histology characterized by well-
preserved pulmonary alveoli and bronchioles, whereas 
those infected with rPR/8 × MINS exhibited mild intersti-
tial and suppurative pneumonia characterized by slightly 
thickened alveolar septa, with moderate hyperplasia of 
type II pneumonocytes and infiltration of a small num-
ber of mononuclear cells in the alveoli and alveolar septa. 
Mice infected with rPR/8 exhibited interstitial and sup-
purative pneumonia characterized by disrupted lung 
parenchyma, notably thickened alveolar septa due to 
type II alveolar cell hyperplasia, and marked infiltration 
of lymphocytes and mononuclear cells in the alveoli and 
interstitium (Figure 3).
Induction of cytokine expression
To analyze pro-inflammatory cytokine expression in 
mice infected with the different NS-expressing viruses, 
the BAL fluid from infected mice was collected at 3, 5, 7, 
and 9 dpi, and secreted cytokines and chemokines were 
measured using a Micro Bead Suspension Array. The lev-
els of IL-6, which stimulates an immune response, and 
CCL5, which plays an active role in recruiting leukocytes 
into the site of inflammation increased by about 100-fold 
(IL-6) or >tenfold (CCL5) after rPR/8 and rPR/8 × MINS 
virus infection, whereas the rPR/8  ×  KYGNS infection 
group showed no significant increase in the levels of 
these two pro-inflammatory cytokines (Figures  4A  and 
B). The results for IFN-γ were similar: the level of this 
cytokine in the rPR/8 and rPR/8 × MINS infection groups 
was significantly higher than that of the rPR/8 × KYGNS 
group, especially at 7 dpi (Figure 4C).
Figure 2 Virulence of the recombinant viruses. The anesthetized 6‑week‑old C57BL/6 mice were inoculated intranasally with 300 EID50 (in 
a 30 μL volume) of PR/8, PR/8 × KYGNS, or PR/8 × MINS virus into a single nostril. Viral lung titers were measured at 3, 5, 7, and 9 dpi (A), and body 
weight changes were monitored daily for 14 days (B). Mortality was measured by defining an endpoint of 25% body weight loss (C). Asterisks indi‑
cate statistically significant differences between groups (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; and ****P ≤ 0.0001).
Page 6 of 9Na et al. Vet Res  (2016) 47:115 
Discussion
The NS1 protein is generally regarded as the primary fac-
tor by which influenza A viruses antagonize the host INF 
response to enhance viral replication [15]. It has been 
suggested that the protein inhibits the polyadenylation of 
cellular mRNA and promotes the addition of poly A tails 
onto viral mRNA and sequesters viral dsRNA, a replica-
tive intermediate, inactivating cellular protein kinase R 
(PKR) and suppressing the IFN response [15, 16].
The inhibition of PKR, which plays a critical role in 
host antiviral responses mediated by IFN, occurs through 
the direct binding of the NS1 protein of influenza A virus 
to PKR. It has been shown that PKR activation is blocked 
by direct binding to the amino acid (AA) residues 123–
127 of NS1 [17]. Furthermore, p85β, a regulatory subunit 
protein of phosphatidylinositol-3-kinase (PI3  K), which 
inhibits apoptosis to ensure viral replication, activates 
PI3K signaling [18]. For this pathway, the binding motifs 
located at AA 164–167 and AA 141–142 in NS1 are 
essential for mediating the interaction between NS1 and 
p85β [18]. PDZ domain-containing proteins may pro-
vide cell signaling and polarity functions in transduction 
pathways, and the binding motif consists of the last four 
C-terminal AA residues of NS1 [19]. In addition, the NS1 
protein binds to the 30-kDa subunit of the cleavage and 
polyadenylation specificity factor (CPSF30) at residues 
AA 144–186 of NS1 and inhibits the 3′- end processing 
of cellular pre-mRNA and then facilitates efficient influ-
enza A virus replication [20]. The alignment of NS1 gene 
AA sequences from KYG11, MA63, and PR/8 viruses 
is presented in Figure  5. Consequently, for the KGY11 
strain, the binding sites associated with the cell signaling 
pathway for the antiviral response were lacking because 
of the premature termination of the NS1 protein.
In particular, horses vaccinated with EIV with a C-ter-
minally truncated NS1 gene showed protection effects 
and significantly reduced clinical signs in response to 
challenge with wild-type EIV [21]. Furthermore, influ-
enza virus with C-terminal NS1 truncations was charac-
terized by not only a high degree of attenuation in vitro 
Figure 3 Lung histopathology of mice infected with the recombinant viruses. Histopathology of lungs from mice infected with each PR/8 
virus containing a different NS gene from a different influenza virus. Mice were inoculated intranasally with each recombinant virus at a dose of 300 
EID50 (in a 30 μL volume), and lung tissues were collected on day 7 following virus inoculation. Images are representative of three mice per group 
(A mock‑infected; B PR/8 × KYGNS—infected; C PR/8 × MINS—infected; and D PR/8‑infected). The bar represents 100 μm. Images were obtained at 
20× magnification.
Page 7 of 9Na et al. Vet Res  (2016) 47:115 
but also a higher replication capacity and stronger IFN 
stimulation in  vivo compared to NS1-deleted virus 
in vivo [22, 23]. Accordingly, it is hypothesized that EIV 
with the C-terminally truncated NS1 gene presents a 
unique advantage for the development of an EIV vaccine.
For these reasons, we hypothesized that the trun-
cated NS gene could affect the replication of the influ-
enza virus, and we established a reverse genetics system 
to characterize this effect in vitro and in vivo. Here, we 
report the extensive characterization of KYG11, an EIV 
strain isolated from a horse that possesses a unique 
naturally mutated NS gene segment encoding a trun-
cated NS1 protein. The truncation did not affect the 
viral replication of rPR/8 in either MDCK or A549 cells; 
rPR/8 × KYGNS showed viral titers comparable to those 
of rPR/8 and rPR/8 × MINS in both cell lines. This find-
ing was in accordance with a previously reported in vitro 
characterization of influenza viruses containing an NS 
Figure 4 Cytokine levels in mice infected with the recombinant viruses. The concentrations of induced cytokines and chemokines were 
determined in the infected mice (n = 3). Levels of (A) IL‑6, (B) CCL5, and (C) IFN‑γ were measured in bronchoalveolar lavage fluids harvested at 3, 5, 
7, and 9 dpi. Asterisks indicate statistically significant differences between groups (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; and ****P ≤ 0.0001).
Figure 5 The alignment of the amino acid sequences of the NS1 gene from KYG11, MA63, and PR/8 viruses. The 23‑nt deletion results in 
a frameshift, generating a premature stop codon and a truncated NS1 protein.
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gene segment with a long deletion [24]. Nevertheless, the 
finding of no difference in growth kinetics between PR8-
based recombinant viruses containing NS1 from KYG11 
and MA63 in  vitro remains controversial because both 
viruses previously showed notable differences in growth 
kinetics in MDCK cell culture [2]. Probably, there are 
mechanisms other than those involving the NS1 protein 
used to evade the antiviral effects of interferon in cells, 
and several factors may contribute to the growth effi-
ciency of influenza virus, in particular PR/8, although the 
NS1 protein is thought to play a significant role in virus 
replication [22]. Accordingly, the functional roles of viral 
factors that affect growth characteristics need to be fur-
ther characterized.
However, the NS gene of the KYG11 strain when 
inserted into the PR/8 background conferred dramati-
cally attenuated pathogenicity in mice. Higher viral loads 
in the lungs, significant weight loss, and 100% mortal-
ity following infection with the rPR/8 or rPR/8 ×  MINS 
virus were observed in mice, in contrast to what was 
seen in rPR/8  ×  KYGNS infections with an equiva-
lent dose. To explain the possible association between 
reduced pathogenicity and the truncated NS gene, pro-
inflammatory cytokines in the lungs of infected mice 
were measured. In assays for a panel of cytokines, infec-
tion with rPR/8 × KYGNS did not induce overexpression 
of pro-inflammatory cytokines (IL-6, CCL5, and IFN-γ) 
on the contrary to what was observed with the two other 
viruses.
In human volunteers infected with influenza viruses, 
increased IL6 levels were associated with rapid activation 
of the innate immune response and pathological signs 
[25, 26]. Furthermore, IL-6 was strongly upregulated in 
ferrets infected with virulent strains of H1N1 and H3N2 
[27]. CCL5 is a potent chemotactic cytokine that recruits 
Th1 and Th2 pro-inflammatory cells and contributes to 
immunopathology by activating cytotoxic T lymphocytes 
in the lungs following influenza virus infection [28, 29]. 
IFN-γ is a pro-inflammatory cytokine with immune reg-
ulatory activities; it also plays a role in the activation of 
macrophages and differentiation of Th1 cells from T cells. 
Increased levels of IFN-γ in response to influenza virus 
infection expand the virus-specific T cell population and 
enhance the natural killer cell response [30–32].
In this study, the elevated levels of three pro-inflamma-
tory cytokines may have contributed to the prominent 
infiltration of lymphocytes and suppurative pneumonia 
in mice infected with rPR/8 or rPR/8 ×  MINS, whereas 
the normal lungs of the rPR/8  ×  KYGNS-infected mice 
may be associated with the virtually unchanged expres-
sion of the pro-inflammatory cytokine expression. A sim-
ilar finding regarding pro-inflammatory cytokines and 
lung pathology associated with an H5N1 influenza virus 
NS gene with a deletion was previously reported [11]. 
This group also found that a PR/8 influenza virus engi-
neered to incorporate the NS gene of a low pathogenic 
virus showed attenuated pathogenicity in mice, char-
acterized by reduced production of pro-inflammatory 
cytokines [11]. Mutations or deletions within the NS1 
gene have been shown to affect the ability of influenza 
viruses to antagonize IFN production and to alter the vir-
ulence of influenza viruses in different hosts [11, 15, 33, 
34].
In this study, an attenuation of the virulence in mice 
of recombinant PR/8 containing the truncated NS gene 
segment (a nucleotide deletion from position 326 to 
348) derived from H3N8 EIV was observed. Our results 
suggest that the C-terminal moiety of NS1 harbors viru-
lence determinants for influenza viruses and therefore 
might be an appropriate target for the development of 
antiviral drugs and vaccine candidates against equine 
influenza.
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